Member Info for Candid

I see today’s news as positive and and an over-reaction by YCA sellers. If KAP triggered this option it means there is likely a shortage of U308 in the spot market and hence they need to source it in the short term from whatever options are currently available.
Also I think Sprott Physical Uranium Trust will soon begin another big purchase program as they have surplus cash for buying. Then once the SPUT starts trading on NYSE this buying activity will grow.

I do not see this as anything to worry about, when a company is growing then a full migration to a proper listing (such as Nasdaq) is a good move. With potential FDA approval this week I would not be selling and have added more. The AIM delisting is planned in January so plenty of time to sell for those who don’t want to hold the shares in Nasdaq.

OBD has been drifting lower on lack of news and probably an overhang of shares due to a seller.
However I think this is a good entry point and the recent director’s purchase of 2,500,000 shares (£1.125m) is significant. This level of investment happens when there is high confidence of the company’s growth.
Launch of the Universal Immuno-Oncology (IO) response test is near.

Didn’t mean to rock the boat regarding efficacy. It’s a treatment to help mitigate the symptoms rather than a cure, so it can get misinterpreted. However the trial proved that patients did benefit from faster wound closure and that in itself is a significant help.
My view is that approval will be achieved from both FDA and EMA. Remember that an EMA approval already exists for partial thickness wounds.
As it’s on a priority review I think this will come in the coming days, there’s a chance the date can get pushed out but I think if that was the case we would have been notified already about a date extension.

https://www.biopharmcatalyst.com/calendars/pdufa-calendar

Anyone seen any broker research about the chances of a successful approval? Got to be quite high as the safety record is good. Could FDA still approve if the efficacy is low to moderate? I’m guessing yes as something is better than nothing treatment wise.

I think recent price weakness is due to a few factors, 1) previous RMP holders selling up as they were not able to sell for a few months, 2) relatively unknown yet in UK, do not think many investors have looked at these yet, they don’t even come up on the VOX search yet, 3) Australian investors were holding this up quite well prior to the AIM relisting, where they were trading in the region of 13p

Brucelee, I’ve been able to trade FME (on ii) since they were relisted on AIM around 3 weeks ago. If you previously held RMP (in AIM) your broker should have sorted this out by now and reinstated your holdings in FME (on AIM), unless they transferred them onto ASX for you while they were delisted on AIM. You should speak to your broker as it’s their responsibility.

After such a fast rise to $51 spot (approx 70% rise), there was bound to be a pullback. Not sure how much influence SPUT had in a pullback, they don't sell their physical holdings so factors driving down spot price are likely to be other entities selling.
I still think the spot price is heading much higher in the months ahead.
If I’m not wrong YCA is trading at quite a premium right now, ($38 spot translates to around 290p NAV), so perhaps the market is pricing in a rebound in the spot price ahead.
What’s the betting on YCA raising more funds to purchase more uranium? I know they have raised twice already this year in March and July so am not sure if rules permit them to raise again this year.

Just read it and as usual a comprehensive annual report with a lot of detail and quite a few news worthy items. My key takes are:

1) As at the date of this report, the Group had received US$1.5M in cash for the 9 Kalahari Copper Belt licences being sold. (I assume the Sandfire shares are soon to follow)

2) In June 2021, Glenover received confirmation that DWS had approved their tailings facility design and waste management plan, and NNR has approved its nuclear license. Glenover is now in the process of securing a guarantee for environmental remediation. (I would think this means the Mining Rights are very close now as that was the final approval)

3) During the period under review, we have seen renewed interest in the production of non-Chinese rare earth production and the overall value of the project may have increased and could increase further should the interest be maintained.
The potential to conclude a commercial arrangement for part or all of the property exists for the 4th quarter of 2021. All of the test work carried out under the period under review belongs to Glenover and as such we have a strong platform to develop one or more of the opportunities from a much stronger test work basis.

So in summary I think GLR is very well cashed up to progress it’s own Botswana, Kashi*tu, Ferber exploration, while at the same time sit back and reap the rewards from Star Zinc mining and Sandfire exploration and also progress a Glenover sale/major partnership for both phosphate rock and rare earths.

Lets not forget that LBE’s current portfolio of 7 exploration targets are predominantly gas (75% gas, 25% oil).
With natural gas prices going through the roof this year, it couldn’t be a better time.

At Cheyeza East where the massive sulphide mineralisation was discovered they are still drilling the 1st hole and are now looking to expand the drill programme. So it depends, if they send samples to the lab hole-by-hole or once the further holes are completed. In the meantime there could well be further announcements when handheld XRF results show significant copper grades as this news is material and is usually announced asap.
At Fwiji drilling they have almost completed the drilling program and will send cores to lab shortly with results prob in a few weeks. So lots to look forward to.

Congrats to the exploration team at ARCM, they always believed in the geology of these licences and have been patiently drilling. With this 1st hole at CE it’s looking like the first significant indication of a big copper discovery.

The market has not priced in the potential here, in 2021 ongoing exploration in 5 separate projects for gold, copper, uranium/vanadium, tungsten. Any one of these can justify the market cap alone.

Welcome news today as this seems to be one of the main reasons holding this back in recent months.
Now can we have some positive updates on the rest of the portfolio: GLR’s Botswana copper exploration on it’s own concessions, Star Zinc, Kash*tu, Glenover, Ferber.

Yep this is so unfortunate, if the final approval was granted the share price would be 10x from here when comparing to peer companies that have shot up recently in the current uranium bull market. There is still an outside chance that the decision is reversed following the submitted improvements report and the independent technical evaluation that dismisses the arguments against the processing plant. However this decision seems politicised, so not sure how the appeal process will play out.
There was an evaluation of a rare earths potential in BKY’s concessions, but am not sure how far this study has progressed.

Solid rise today, world’s top uranium miner trending higher.

Last week was massive for uranium, a big break-out. I’ve been waiting for this move for years (along with many other patient uranium investors). There have been attempts to break-out before but this looks like the real deal. Backed by pure demand and supply fundamentals.
I’m fully loaded on various miners, mainly Canadian and Australian ones. What’s people’s views on here about the companies most likely to hit the big time? Most have risen a lot (from multi-year lows) and while they could have much further to run, some will do better than others.

I feel that the Rackla/Goldenhawk deal is just around the corner and may be the catalyst to get this climbing higher. (although I’m still a bit peeved that they are offloading a 3.1m oz gold asset for what seems like not that much)
The big prize must be the copper in Zambia.

Not surprised that we’re seeing seasoned investors here. The risk-return is very appealing .
From 7 targets already planned, the chances of hitting at least one must be high and likely transformational for LBE

With multi-target exploration about to start this will likely see a wave of new investors, traders, fomo crowd. There aren’t a lot of shares available with such a tightly held share register, free float must be small, expect to see price moves on low volumes